The
only clinical trial data on the experimental Ebola drug ZMapp shows it
is 100% effective in monkey studies, even in later stages of the
infection.
The researchers, publishing their data in Nature, said it was a “very important step forward”.
Yet the limited supplies will not help the 20,000 people predicted to be infected during the outbreak in West Africa.
And two out of seven people given the drug, have later died from the disease.
ZMapp
has been dubbed the “secret serum” as it is still in the experimental
stages of drug development with, until now, no public data on
effectiveness.
Doctors have turned to it as there is no cure for Ebola, which has killed more than 1,500 people since it started in Guinea.
Researchers
have been investigating different combinations of antibodies, a part of
the immune system which binds to viruses, as a therapy.
Previous
combinations have shown some effectiveness in animal studies. ZMapp is
the latest cocktail and contains three antibodies.
Trials on 18 rhesus macaques infected with Ebola showed 100% survival.
This
included animals given the drug up to five days after infection. For the
monkeys this would be a relatively late stage in the infection, around
three days before it becomes fatal.
No comments:
Post a Comment